Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent Biologics's Enterprise Value for the quarter that ended in Dec. 2025 was $14,724 Mil.
Innovent Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $128 Mil. Innovent Biologics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 0.88%.
The historical rank and industry rank for Innovent Biologics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
IVBXF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -288.4 Med: -2.94 Max: 0.9
Current: 0.53
During the past 10 years, the highest Earnings Yield (Joel Greenblatt) of Innovent Biologics was 0.90%. The lowest was -288.40%. And the median was -2.94%.
IVBXF's Earnings Yield (Joel Greenblatt) % is ranked better than 78.99% of 1347
companies
in the Biotechnology industry
Industry Median: -9.78
vs IVBXF: 0.53
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Innovent Biologics's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Innovent Biologics Earnings Yield (Joel Greenblatt) % Related Terms
Innovent Biologics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innovent Biologics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Innovent Biologicss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 0.88% mean?
Innovent Biologics (IVBXF) has a Earnings Yield (Joel Greenblatt) % of 0.88% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Innovent Biologics and its competitors. According to the industry distribution chart, Innovent Biologics ranks #283 out of 1347 companies in the Biotechnology industry, placing it in the top 21%.
Is Innovent Biologics' Earnings Yield (Joel Greenblatt) % too high?
Innovent Biologics' current Earnings Yield (Joel Greenblatt) % is 0.88%. Based on the distribution chart, Innovent Biologics ranks #283 out of 1347 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Innovent Biologics has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #283 out of 1347 companies for Earnings Yield (Joel Greenblatt) %. This places Innovent Biologics in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Innovent Biologics and its competitors. Innovent Biologics's current Earnings Yield (Joel Greenblatt) % is 0.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (IVBXF) is currently considered Fairly Valued. The stock's GF Value™ is $13.44, compared to a current price of $13.61 — trading 1.3% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 0.88%. Innovent Biologics' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Innovent Biologics (IVBXF), the current Earnings Yield (Joel Greenblatt) % is 0.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (IVBXF) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be overvalued.
The current stock price of $13.61 is trading 1.3% above its estimated GF Value™ of $13.44.
GuruFocus considers Innovent Biologics to be Fairly Valued.
Key valuation signals for IVBXF:
Earnings Yield (Joel Greenblatt) %: 0.88%
GF Value™: $13.44 vs. price of $13.61 (1.3% above fair value)
No single metric tells the full story. See the IVBXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
77GF Score
Get the complete analysis for IVBXF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVBXF has been successfully added to your 
